Compare Robinhood Markets, Inc. (HOOD) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Robinhood Markets, Inc. vs State Street SPDR S&P Biotech ETF — how do they compare? Robinhood Markets, Inc. trades at $108.91 (market cap $96.21B), while State Street SPDR S&P Biotech ETF trades at $154.08 (market cap $10.11B). The key difference: Robinhood Markets, Inc. is far larger — about 9.5× State Street SPDR S&P Biotech ETF's market cap, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Robinhood Markets, Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Robinhood Markets, Inc. for 75 Days and State Street SPDR S&P Biotech ETF for 38 Days on average.
| HOOD | XBI | |
|---|---|---|
Market Cap | $96.21B | $10.11B |
Volume | 22,572,153 | 12,903,266 |
Sector | Financials | Broad Market / Factor |
52-Week High | $152.46 | $169.55 |
52-Week Low | $65.16 | $104.99 |
Typical Hold Time | 75 Days | 38 Days |
Enterprise Value | $102.75B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Robinhood (HOOD) trades at $108.95, down 0.51% on the day, with a bullish technical signal and strong analyst consensus. The stock shows robust fundamentals with 2025 revenue of $4.47B and net income of $1.88B, though valuation ratios like P/E of 47.35 are elevated. Recent news highlights expansion into 24/7 stock trading and AI-driven features, signaling growth initiatives.
Outlook remains positive with a consensus price target of $137.53, offering ~26% upside, but risks include high valuation sensitivity and competitive pressures in the brokerage sector. Earnings beat in two of the last three quarters supports growth trajectory, though investors should monitor execution on new product launches and regulatory developments.
XBI trades at $153.84, up 2.4% today, but technical indicators signal a bearish trend with resistance at $154. The ETF's modified equal-weight structure offers broad biotech exposure, benefiting from M&A activity and positive clinical catalysts, though key financial ratios are unavailable. Recent news highlights sector optimism driven by cancer vaccine breakthroughs and improved capital access.
Outlook is mixed: bullish sentiment from innovation and M&A supports growth potential, but high volatility and expense ratios relative to peers pose risks. Analyst consensus is neutral (100% Hold), suggesting cautious optimism amid technical bearishness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Robinhood Markets, Inc.
Robinhood Markets, Inc. operates a financial services platform. The Company offers brokerage and cash management applications such as stocks, exchange-traded funds, options, and cryptocurrency. Robinhood Markets serves clients in the United States.
Read more on HOOD →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
